Geode Capital Management
CTNM

Geode Capital Management’s Contineum Therapeutics CTNM Stock Holding History

Geode Capital Management’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.4M Buy
693,188
+411,150
+146% +$5.39M ﹤0.01% 2465
2026
Q1 		$3.69M Buy
282,038
+68,169
+32% +$914K ﹤0.01% 2888
2025
Q4 		$2.45M Buy
213,869
+2,819
+1% +$32.2K ﹤0.01% 3091
2025
Q3 		$2.48M Buy
211,050
+139,747
+196% +$1.13M ﹤0.01% 3105
2025
Q2 		$283K Sell
71,303
-121,748
-63% -$529K ﹤0.01% 3757
2025
Q1 		$1.35M Buy
193,051
+4,643
+2% +$42.2K ﹤0.01% 3196
2024
Q4 		$2.76M Buy
188,408
+59,732
+46% +$946K ﹤0.01% 3017
2024
Q3 		$2.46M Sell
128,676
-27,745
-18% -$532K ﹤0.01% 3060
2024
Q2 		$2.75M Buy
+156,421
New +$2.52M ﹤0.01% 3021

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management's CTNM Position: Q2 2026 in Review

Geode Capital Management increased its Contineum Therapeutics (CTNM) stake by 146% in Q2 2026, buying an estimated $5.39M and bringing the position to 693,188 shares worth $11.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2465.

Geode Capital Management first reported a position in CTNM in Q2 2024 and has held it in 9 quarters since. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

  • Geode Capital Management held 693,188 shares of Contineum Therapeutics worth $11.4M as of Q2 2026.
  • Geode Capital Management bought 411,150 Contineum Therapeutics shares in Q2 2026, an estimated $5.39M.
  • Contineum Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2465 holding.
  • Geode Capital Management first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.